Aberrant promoter methylation may be responsible for the control of CD146 (MCAM) gene expression during breast cancer progression.
In conclusion, our study revealed, for the first time, that aberrant methylation maybe involved in expression control of CD146, a very potent EMT inducer in breast cancer cells. Altogether, the data obtained may provide the basis for novel therapies as well as diagnostic approaches enabling sensitive and very accurate detection of breast cancer cells.
PMID: 31826047 [PubMed - as supplied by publisher]
Source: Acta Biochim Pol - Category: Biochemistry Authors: Dudzik P, Trojan SE, Ostrowska B, Lasota M, DuliĆska-Litewka J, Laidler P, Kocemba-Pilarczyk KA Tags: Acta Biochim Pol Source Type: research
More News: Biochemistry | Breast Cancer | Cancer | Cancer & Oncology | Epithelial Cancer | Genetics | Melanoma | Prostate Cancer | Skin Cancer | Study